DETAILED ACTION
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Claim Rejections - 35 USC § 103
In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status.
The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action:
A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made.
The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows:
1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.
This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention.
Claims 1-20 are rejected under 35 U.S.C. 103 as being unpatentable over the combination of WO21/195024 and US2005/0191310.
The claims of the present application are drawn to compositions comprising the compound of formula I and cyclodextrin. Dependent claims provide the compound is TQL-1055 (claim 2) and wherein the cyclodextrin is various common cyclodextrins such as α, β, or γCD. The claims also provide formula I is a potassium salt and where the composition further comprises an antigen such as one associated with a bacteria or virus and where the virus is SARS-CoV-2 or Varicella Zoster. The compositions are taught to be pH stable for at least 12, 24, or 36 months, and to have a pH between approximately 7-8. Also claimed are methods of conferring resistance to an infection with the same.
‘024 teaches to make formulations of the same compound of formula I and suggests incorporating cyclodextrin therein – see for example claims 1, 16, and 19 therein. ‘024 also teaches their compositions have a pH of between approximately 7-8, and also 7-7.5, 7.5-8, and 7.4 (see page 55, lines 4-16). The formulations are taught to optionally comprise the potassium salts of the compounds (see page 49, line 31). The compositions are taught to optionally include antigens and be administered to induce a response to an antigen (see page 53, lines 20-32). Regarding the limitations of the composition being stable after certain periods of time – this would be seen to be met upon the making of the obvious compositions as it is a result of the compositions ingredients. What is not exemplified is the actual cyclodextrin containing composition.
‘310 discloses saponin (QS-21) compositions comprising cyclodextrins, preferably hydroxypropyl-β-cyclodextrin which is taught to reduce QS-21 (the saponin therein) lysis in red blood cels in vitro (see [0029]). Table 1 therein discloses the use of various cyclodextrins in their saponin containing adjuvant compositions. ‘310 teaches their compositions can enhance the immune response to any antigen and provide various antigens to be used with their compositions including viral antigens (see [0031]).
It would have been obvious to a skilled artisan to make the compositions claimed with ‘024 and ‘310 before them since they both suggest the same. ‘310 teaches various cyclodextrin adjuvant systems for saponins, and ‘024 teaches the saponins claimed herein, and also suggest adding cyclodextrin thereto. The art teaches the same compounds herein can be used in adjuvant systems for inducing a response in a subject and suggest adding cyclodextrin thereto. For example, claim 19 of ‘024 is drawn to the species of claim 2 herein together with an additional agent wherein cyclodextrin is one of 12 agents to chose from to be added to the composition. A skilled artisan would have found it obvious to add any of the 12 recited agents, including cyclodextrin as required herein, and would especially be motivated to use cyclodextrin in view of the beneficial effects taught by ‘310. Further, it would have been obvious to add various antigens, such as those from SARS-CoV-2 or Varicella Zoster in an effort to induce an immune response in patients having these diseases as both references teach various types of antigens can be utilized. Likewise, all of the different cyclodextrins are seen to be obvious variants as there is nothing in the present application which shows a criticality or anything unexpected from one cyclodextrin to another, thus it would be obvious to use various art known cyclodextrins in the compositions of ‘024.
Conclusion
Any inquiry concerning this communication or earlier communications from the examiner should be directed to TRAVISS C MCINTOSH III whose telephone number is (571)272-0657. The examiner can normally be reached Monday-Friday 9AM-5:30PM EST.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Scarlett Goon can be reached at 571-270-5241. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/TRAVISS C MCINTOSH III/ Primary Examiner, Art Unit 1693